News
Sarepta Therapeutics Announces Leadership Change and Equity Deal November 26, 2024 — 07:48 am EST Written by TipRanks Auto-Generated Newsdesk for TipRanks -> ...
Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...
Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring in Wednesday’s after-hours session after the company announced a ...
8d
Pharmaceutical Technology on MSNSarepta Therapeutics to cut 500 jobs amid restructuring
Sarepta Therapeutics is set to cut 500 jobs as part of its restructuring and pipeline prioritisation plan, which is expected to result in annual cash cost savings of $120m in 2026. With its pipeline ...
Reeling from the deaths of two patients who took Duchenne muscular dystrophy gene therapy Elevidys, Sarepta is launching a ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results